Mike Van

Mike Van, PhD, is an Associate at Sofinnova Investments, based in Stanford, CA, where he focuses on private equity investments in the biopharmaceutical sector. Promoted to Associate in 2024 after serving as an Analyst, he is responsible for identifying, evaluating, and supporting promising biopharma companies, leveraging a rigorous scientific and investment approach to drive portfolio growth and value creation.

His expertise centers on the biopharmaceutical industry, with particular emphasis on therapeutics, drug development, and transformative life sciences technologies. Before joining Sofinnova in 2022, he held roles as a venture fellow and consultant across various biotech companies, contributing to projects in business development, assay design, and product innovation for organizations such as Maze Therapeutics, Octant, and Wearlinq. Notably, he was a managing partner of the Mythos Biotechnology Fund, a student-led public biotech investment club, demonstrating leadership and sector insight.

Mike earned his PhD in Biology from Stanford University, where his research in the Bintu laboratory advanced CRISPR-based epigenome editing tools through synthetic biology and high-throughput screening. He also holds a Bachelor of Science in Biochemistry and Molecular Biology from UC Davis. His strong scientific foundation, combined with practical experience in biotech and venture investing, underpins his contributions to Sofinnova and the broader investment community.